4.6 Article

Linking COVID-19 and Parkinson's disease: Targeting the role of Vitamin-D

Journal

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2021.10.042

Keywords

alpha-synuclein; COVID-19; Neurodegeneration; Neuroinflammation; Parkinson's disease; SARS-CoV-2

Ask authors/readers for more resources

COVID-19 pandemic may exacerbate the progression of Parkinson's disease, and certain virus infections are also associated with the development of Parkinsonism. Coronavirus primarily infects alveolar cells, potentially leading to acute respiratory distress syndrome. Intake of vitamin D may help reduce the risk and severity of COVID-19 in Parkinsonian patients.
COVID-19 pandemic has a major effect on world health, particularly on individuals suffering from severe diseases or old aged persons. Various case studies revealed that COVID-19 might increase the progression of Parkinson's disease (PD). Coxsackievirus, dengue virus Epstein-Barr virus, hepatitis C virus, Japanese encephalitis, Western equine encephalomyelitis virus, West Nile virus, and human immunodeficiency virus have all been linked to the development of transient or permanent parkinsonism, owing to the induction of neuroinflammation/hypoxic brain injury with structural/functional damage within the basal ganglia. Coronavirus mainly infects the alveolar cells and may lead to acute respiratory distress syndrome. SARS-CoV-2 invades cells via the ACE2 receptor, which is widely expressed in the central nervous system, where the virus may precipitate or accelerate dementia. SARS-CoV-2 could enter the central nervous system directly by the olfactory/vagus nerves or through the bloodstream. Here, we talked about the importance of this viral infection in terms of the CNS as well as its implications for people with Parkinson's disease; anosmia & olfaction-related impairments in COVID-19 & PD patients. And, also discussed the role of vitamin D to sustain the progression of Parkinson's disease and the COVID-19; regular vitamin D-3 consumption of 2000-5000 IU/day may reduce the risk and severity of COVID-19 in parkinsonian patients. (C) 2021 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available